mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. - Wikidata - awgldk - TriplyDB

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

http://www.wikidata.org/entity/Q30415483

about

Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.Merlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury.A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.The mTOR signaling pathway as a treatment target for intracranial neoplasms Neurofibromatosis-related tumors: emerging biology and therapies.A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2 Role of Merlin/NF2 inactivation in tumor biology.mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.CNS Tumors in Neurofibromatosis.Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.Schwann cell development, maturation and regeneration: a focus on classic and emerging intracellular signaling pathways An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth.A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas.Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation.Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.Role of mTORC1 Controlling Proteostasis after Brain Ischemia.[Pathogenesis and molecular pathology of vestibular schwannoma].Update from the 2013 International Neurofibromatosis Conference.Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.Emerging Medical Treatments for Meningioma in the Molecular Era

P2860

Q27853117-5A7075DC-6721-4596-8716-FDAF4C8FD5D8 Q30373369-FE8C37BE-C221-49ED-9DAA-C00D118DC5F7 Q30396975-0C9CA3A8-26FA-467C-8B26-EC3D8C5D5129 Q34886859-D924CFE3-6176-44EC-9E97-6DBA3B995796 Q35218073-EF6678B8-FB9E-448E-B366-8866DFC2AF04 Q35380714-656CF3AE-AFE3-4B8D-86D3-53D8B164295B Q36189820-532C9198-6F6A-4D04-B915-E1F853CFD113 Q37697798-CBE59D5B-C3A9-4215-93CC-0A8C56CC9C0C Q38666243-1F6EC75A-7E69-4C16-A625-43AE54FF93DC Q38713914-1E2A2BED-B6FE-4803-A71A-D1664740947E Q41139111-578ABD94-44C2-45F7-A7E6-9E4C34DA9643 Q41429732-31D9DB2B-1B01-4CD5-8ACC-0D5F6CA1131F Q44526324-8F92685E-FE4F-4795-993D-A060C9C9E34F Q46155699-9972B6F4-78E6-40F9-BD82-518B6812AEA5 Q48674799-5308A0C5-DF62-4ECE-848C-EE24A1254092 Q50352494-1BD36239-7645-4C4C-90AB-1883D605B745 Q50879137-AAE7FA55-64EB-472F-9E2E-DB956D2A436A Q52369978-FD43D47B-6A80-4A6E-9C95-DB75B8E948F2 Q52991168-C390CC36-6392-41A6-AC2F-D0A3754B2044 Q53083642-BA1A0E10-6473-41C3-A4ED-8178A410EFF6 Q53316010-1CF68514-47CA-4138-8C5A-67893AE538ED Q58798211-49C4A449-1D57-4483-8D03-EE022E261402

P2860

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

http://www.wikidata.org/entity/Q30415483

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

@ast

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

@en

type

label

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

@ast

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

@en

prefLabel

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

@ast

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

@en

P1433

Q30415483-EE3C2EB2-AD75-48B7-8B1F-24440FC42072

P1476

Q30415483-8C1FA6F9-A135-4864-9E53-B162537914B4

P2093

Q30415483-032AAEB4-C068-4AFF-BCE8-3D4210E1DDCC

Q30415483-37CB9142-24CD-4BD8-BAA8-E3889B546A0F

Q30415483-4E7FECEA-0979-46E6-87E0-B01DF19A1F0E

Q30415483-803007DD-DBBC-409F-87A0-5260F2A4888C

Q30415483-903CD3B1-5050-4812-8C0A-EE94EDCD8F8F

Q30415483-C43B57DA-36BC-45A6-ACE3-3AF648A6EE0E

Q30415483-DD1F6BB8-994E-445E-80B4-E1F5E6BFE245

Q30415483-FDCAB541-4BF8-4EA3-9D0C-375C53FF8DE8

P2860

Q30415483-077F01C5-F859-48A8-BA56-18155012B12F

Q30415483-0906B7E1-03D8-4C92-B794-F7676F25367B

Q30415483-0964070C-FDF4-4ED1-92C0-C405F84F0A7F

Q30415483-0B383783-0BAA-40B6-81B2-6D2B6CA1E6F4

Q30415483-15A08608-01F3-422C-8D0A-CBB34CAC3528

Q30415483-1CE82723-8E2A-419A-9F52-BA9406A9AB63

Q30415483-2218F4BF-05E7-4DCA-924B-05E872B958FE

Q30415483-2B57786F-B931-4502-92F8-549D4C305A07

Q30415483-36C29135-F6D2-42F1-B929-187CC61BECD3

Q30415483-42D86DD1-CD15-4FEC-80B0-64F40E643C45

P304

Q30415483-2A0E3494-9853-45E2-B7D8-6C4F7A873B24

P31

Q30415483-2585D515-74F7-4FFC-9937-83D2BB7A5C4A

P356

Q30415483-A71C8A30-E9F3-4DA3-8901-18B307BB2362

P433

Q30415483-496DA773-9B1C-4460-95F8-124A77987A77

P478

Q30415483-5221627B-853B-41E1-8581-EE16EFB28D39

P50

Q30415483-A7FE93A5-EB69-4E45-B900-251D737ACDA6

Q30415483-EBCABB5F-CF2D-43D0-8617-ED1811DB15B4

Q30415483-F730B3BE-4BEE-491A-BBD6-691E95F6269D

P577

Q30415483-ACF72D2E-E9D6-4982-A149-83285BC30A33

P5875

Q30415483-D4FD2A84-1ABC-44DD-9061-70A8B4D1B4FD

P698

Q30415483-D9B61DE0-7C3B-4487-B960-CC2224219745

P932

Q30415483-21FFD4CA-2EE4-4073-B342-0A43200AE7A8

P356

P1433

P1476

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.

@en

P2093

Fabrice Chareyre

http://www.w3.org/2001/XMLSchema#string

Karo Tanaka

http://www.w3.org/2001/XMLSchema#string

Laurel M Fisher

http://www.w3.org/2001/XMLSchema#string

Laurence Valeyrie-Allanore

http://www.w3.org/2001/XMLSchema#string

Marco Giovannini

http://www.w3.org/2001/XMLSchema#string

Michel Kalamarides

http://www.w3.org/2001/XMLSchema#string

Nicolas-Xavier Bonne

http://www.w3.org/2001/XMLSchema#string

Rocky Adams

http://www.w3.org/2001/XMLSchema#string

P2860

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2

mTOR signaling in growth control and disease

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability

Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

P304

493-504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOT242

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Pierre Wolkenstein

Stephane Goutagny

P577

2014-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259700239

http://www.w3.org/2001/XMLSchema#string

P698

24414536

http://www.w3.org/2001/XMLSchema#string

P932

3956353

http://www.w3.org/2001/XMLSchema#string